Pathologic tearfulness after limbic encephalitis: A novel disorder and its neural basis.


Journal

Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060

Informations de publication

Date de publication:
24 03 2020
Historique:
received: 04 07 2019
accepted: 03 10 2019
pubmed: 26 1 2020
medline: 24 7 2020
entrez: 26 1 2020
Statut: ppublish

Résumé

We investigated the nature and neural foundations of pathologic tearfulness in a uniquely large cohort of patients who had presented with autoimmune limbic encephalitis (aLE). We recruited 38 patients (26 men, 12 women; median age 63.06 years; interquartile range [IQR] 16.06 years) in the postacute phase of aLE who completed questionnaires probing emotion regulation. All patients underwent structural/functional MRI postacutely, along with 67 age- and sex-matched healthy controls (40 men, 27 women; median age 64.70 years; IQR 19.87 years). We investigated correlations of questionnaire scores with demographic, clinical, neuropsychological, and brain imaging data across patients. We also compared patients diagnosed with pathologic tearfulness and those without, along with healthy controls, on gray matter volume, resting-state functional connectivity, and activity. Pathologic tearfulness was reported by 50% of the patients, while no patient reported pathologic laughing. It was not associated with depression, impulsiveness, memory impairment, executive dysfunction in the postacute phase, or amygdalar abnormalities in the acute phase. It correlated with changes in specific emotional brain networks: volume reduction in the right anterior hippocampus, left fusiform gyrus, and cerebellum, abnormal hippocampal resting-state functional connectivity with the posteromedial cortex and right middle frontal gyrus, and abnormal hemodynamic activity in the left fusiform gyrus, right inferior parietal lobule, and ventral pons. Pathologic tearfulness is common following aLE, is not a manifestation of other neuropsychiatric features, and reflects abnormalities in networks of emotion regulation beyond the acute hippocampal focus. The condition, which may also be present in other neurologic disorders, provides novel insights into the neural basis of affective control and its dysfunction in disease.

Identifiants

pubmed: 31980582
pii: WNL.0000000000008934
doi: 10.1212/WNL.0000000000008934
pmc: PMC7274928
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1320-e1335

Subventions

Organisme : Medical Research Council
ID : MR/K010395/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 104079/Z/14/Z
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom

Informations de copyright

Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Références

Brain. 2001 Sep;124(Pt 9):1708-19
pubmed: 11522574
J Neurol Neurosurg Psychiatry. 2015 Jul;86(7):735-42
pubmed: 25185210
J Autism Dev Disord. 2004 Apr;34(2):163-75
pubmed: 15162935
Eur J Neurol. 2018 Aug;25(8):1011-1016
pubmed: 29667271
Ann Neurol. 2006 Jan;59(1):178-81
pubmed: 16278841
J Neurophysiol. 2011 Nov;106(5):2322-45
pubmed: 21795627
Neurol Clin Pract. 2018 Dec;8(6):472-481
pubmed: 30588376
Neurology. 2012 Apr 10;78(15):1130-7
pubmed: 22459674
Brain. 2018 Feb 1;141(2):348-356
pubmed: 29272336
Seizure. 2016 Dec;43:48-55
pubmed: 27886629
J Pers Assess. 2014;96(6):619-31
pubmed: 24730588
J Neurol Neurosurg Psychiatry. 2014 Apr;85(4):387-91
pubmed: 24403282
J Neurol Neurosurg Psychiatry. 1997 Jul;63(1):89-93
pubmed: 9221973
JAMA Neurol. 2017 Jan 1;74(1):50-59
pubmed: 27893017
Brain Neurosci Adv. 2017 Aug 4;1(1):
pubmed: 28944298
Neuron. 2010 Jan 14;65(1):7-19
pubmed: 20152109
J Neurosci. 2016 Nov 30;36(48):12157-12167
pubmed: 27903725
Sci Rep. 2018 Jun 22;8(1):9561
pubmed: 29934574
Psychosomatics. 2011 Jan-Feb;52(1):78-81
pubmed: 21300199
J Comp Neurol. 1989 Nov 1;289(1):53-73
pubmed: 2478597
J Neurol Neurosurg Psychiatry. 2006 Dec;77(12):1376-80
pubmed: 17110751
Neurology. 2009 May 12;72(19):1703-5
pubmed: 19433746
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Seizure. 2013 Mar;22(2):136-40
pubmed: 23318046
J Neuroimmunol. 2017 Nov 15;312:8-14
pubmed: 28889962
Brain Connect. 2012;2(3):125-41
pubmed: 22642651
J Neuropsychiatry Clin Neurosci. 2009 Winter;21(1):75-87
pubmed: 19359455
Neurology. 2000 May 9;54(9):1805-10
pubmed: 10802788
J Neurol Neurosurg Psychiatry. 2019 Sep;90(9):965-974
pubmed: 31072956
Eur J Paediatr Neurol. 2018 Jan;22(1):190-193
pubmed: 28919330
Arch Neurol. 1988 Sep;45(9):936
pubmed: 3415524
Brain Res. 2008 Sep 26;1232:173-84
pubmed: 18656465
Elife. 2019 Jun 17;8:
pubmed: 31205000
Lancet Neurol. 2016 Apr;15(4):391-404
pubmed: 26906964
JAMA Neurol. 2014 Oct;71(10):1300-4
pubmed: 25133690
Neuroimage. 2007 Oct 15;38(1):95-113
pubmed: 17761438
J Clin Psychol. 1995 Nov;51(6):768-74
pubmed: 8778124
Neurology. 2004 Oct 26;63(8):1364-70
pubmed: 15505150
Neuroimage. 2004 Jun;22(2):676-87
pubmed: 15193596
Neurosci Biobehav Rev. 2004 May;28(3):273-83
pubmed: 15225971
Epilepsia. 2017 Jul;58(7):1181-1189
pubmed: 28555833
Neuroimage. 2011 Jun 1;56(3):907-22
pubmed: 21352927
Neurology. 2014 Aug 12;83(7):620-7
pubmed: 25008395
Psychiatry Res. 2008 Jun 30;159(3):367-75
pubmed: 18374422
J Neurosci. 1990 Sep;10(9):2897-902
pubmed: 2398367
Front Psychol. 2013 Mar 22;4:69
pubmed: 23526601
Proc Natl Acad Sci U S A. 2009 May 12;106(19):8021-6
pubmed: 19414310
Hum Brain Mapp. 2006 Feb;27(2):91-8
pubmed: 16035037
Elife. 2019 Jul 08;8:
pubmed: 31282861

Auteurs

Georgios P D Argyropoulos (GPD)

From the Memory Research Group (G.P.D.A., L.M., C.L., A.R.-F., C.L.-M., O.G., C.R.B.) and Autoimmune Neurology Group (S.R.I.), Nuffield Department of Clinical Neurosciences, University of Oxford; Department of Psychology (L.M.), University of Bath; Maurice Wohl Clinical Neuroscience Institute, Basic and Clinical Neuroscience Department (C.L.), King's College London, UK; Valdecilla Biomedical Research Institute (C.L.-M.), University Hospital Marqués de Valdecilla, Santander, Spain; Medical School (A.Z.), University of Exeter, UK; Department of Brain Sciences (C.R.B.) Imperial College London, UK; and Departamento de Neurología (C.R.B.), Pontificia Universidad Católica de Chile, Santiago. georgios.argyropoulos@ndcn.ox.ac.uk.

Lauren Moore (L)

From the Memory Research Group (G.P.D.A., L.M., C.L., A.R.-F., C.L.-M., O.G., C.R.B.) and Autoimmune Neurology Group (S.R.I.), Nuffield Department of Clinical Neurosciences, University of Oxford; Department of Psychology (L.M.), University of Bath; Maurice Wohl Clinical Neuroscience Institute, Basic and Clinical Neuroscience Department (C.L.), King's College London, UK; Valdecilla Biomedical Research Institute (C.L.-M.), University Hospital Marqués de Valdecilla, Santander, Spain; Medical School (A.Z.), University of Exeter, UK; Department of Brain Sciences (C.R.B.) Imperial College London, UK; and Departamento de Neurología (C.R.B.), Pontificia Universidad Católica de Chile, Santiago.

Clare Loane (C)

From the Memory Research Group (G.P.D.A., L.M., C.L., A.R.-F., C.L.-M., O.G., C.R.B.) and Autoimmune Neurology Group (S.R.I.), Nuffield Department of Clinical Neurosciences, University of Oxford; Department of Psychology (L.M.), University of Bath; Maurice Wohl Clinical Neuroscience Institute, Basic and Clinical Neuroscience Department (C.L.), King's College London, UK; Valdecilla Biomedical Research Institute (C.L.-M.), University Hospital Marqués de Valdecilla, Santander, Spain; Medical School (A.Z.), University of Exeter, UK; Department of Brain Sciences (C.R.B.) Imperial College London, UK; and Departamento de Neurología (C.R.B.), Pontificia Universidad Católica de Chile, Santiago.

Adriana Roca-Fernandez (A)

From the Memory Research Group (G.P.D.A., L.M., C.L., A.R.-F., C.L.-M., O.G., C.R.B.) and Autoimmune Neurology Group (S.R.I.), Nuffield Department of Clinical Neurosciences, University of Oxford; Department of Psychology (L.M.), University of Bath; Maurice Wohl Clinical Neuroscience Institute, Basic and Clinical Neuroscience Department (C.L.), King's College London, UK; Valdecilla Biomedical Research Institute (C.L.-M.), University Hospital Marqués de Valdecilla, Santander, Spain; Medical School (A.Z.), University of Exeter, UK; Department of Brain Sciences (C.R.B.) Imperial College London, UK; and Departamento de Neurología (C.R.B.), Pontificia Universidad Católica de Chile, Santiago.

Carmen Lage-Martinez (C)

From the Memory Research Group (G.P.D.A., L.M., C.L., A.R.-F., C.L.-M., O.G., C.R.B.) and Autoimmune Neurology Group (S.R.I.), Nuffield Department of Clinical Neurosciences, University of Oxford; Department of Psychology (L.M.), University of Bath; Maurice Wohl Clinical Neuroscience Institute, Basic and Clinical Neuroscience Department (C.L.), King's College London, UK; Valdecilla Biomedical Research Institute (C.L.-M.), University Hospital Marqués de Valdecilla, Santander, Spain; Medical School (A.Z.), University of Exeter, UK; Department of Brain Sciences (C.R.B.) Imperial College London, UK; and Departamento de Neurología (C.R.B.), Pontificia Universidad Católica de Chile, Santiago.

Oana Gurau (O)

From the Memory Research Group (G.P.D.A., L.M., C.L., A.R.-F., C.L.-M., O.G., C.R.B.) and Autoimmune Neurology Group (S.R.I.), Nuffield Department of Clinical Neurosciences, University of Oxford; Department of Psychology (L.M.), University of Bath; Maurice Wohl Clinical Neuroscience Institute, Basic and Clinical Neuroscience Department (C.L.), King's College London, UK; Valdecilla Biomedical Research Institute (C.L.-M.), University Hospital Marqués de Valdecilla, Santander, Spain; Medical School (A.Z.), University of Exeter, UK; Department of Brain Sciences (C.R.B.) Imperial College London, UK; and Departamento de Neurología (C.R.B.), Pontificia Universidad Católica de Chile, Santiago.

Sarosh R Irani (SR)

From the Memory Research Group (G.P.D.A., L.M., C.L., A.R.-F., C.L.-M., O.G., C.R.B.) and Autoimmune Neurology Group (S.R.I.), Nuffield Department of Clinical Neurosciences, University of Oxford; Department of Psychology (L.M.), University of Bath; Maurice Wohl Clinical Neuroscience Institute, Basic and Clinical Neuroscience Department (C.L.), King's College London, UK; Valdecilla Biomedical Research Institute (C.L.-M.), University Hospital Marqués de Valdecilla, Santander, Spain; Medical School (A.Z.), University of Exeter, UK; Department of Brain Sciences (C.R.B.) Imperial College London, UK; and Departamento de Neurología (C.R.B.), Pontificia Universidad Católica de Chile, Santiago.

Adam Zeman (A)

From the Memory Research Group (G.P.D.A., L.M., C.L., A.R.-F., C.L.-M., O.G., C.R.B.) and Autoimmune Neurology Group (S.R.I.), Nuffield Department of Clinical Neurosciences, University of Oxford; Department of Psychology (L.M.), University of Bath; Maurice Wohl Clinical Neuroscience Institute, Basic and Clinical Neuroscience Department (C.L.), King's College London, UK; Valdecilla Biomedical Research Institute (C.L.-M.), University Hospital Marqués de Valdecilla, Santander, Spain; Medical School (A.Z.), University of Exeter, UK; Department of Brain Sciences (C.R.B.) Imperial College London, UK; and Departamento de Neurología (C.R.B.), Pontificia Universidad Católica de Chile, Santiago.

Christopher R Butler (CR)

From the Memory Research Group (G.P.D.A., L.M., C.L., A.R.-F., C.L.-M., O.G., C.R.B.) and Autoimmune Neurology Group (S.R.I.), Nuffield Department of Clinical Neurosciences, University of Oxford; Department of Psychology (L.M.), University of Bath; Maurice Wohl Clinical Neuroscience Institute, Basic and Clinical Neuroscience Department (C.L.), King's College London, UK; Valdecilla Biomedical Research Institute (C.L.-M.), University Hospital Marqués de Valdecilla, Santander, Spain; Medical School (A.Z.), University of Exeter, UK; Department of Brain Sciences (C.R.B.) Imperial College London, UK; and Departamento de Neurología (C.R.B.), Pontificia Universidad Católica de Chile, Santiago.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH